Latham & Watkins advised BioXcel Therapeutics, while Davis Polk advised the underwriters in connection with the offering. BioXcel Therapeutics completed a public offering of 2,000,000 shares…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now